
ICON (ICLR) Stock Forecast & Price Target
ICON (ICLR) Analyst Ratings
Bulls say
Icon has demonstrated a positive trend with a gross business awards increase of 11% on a sequential basis, driven by successful partnerships with biotech and pharmaceutical clients. The company has successfully met or exceeded its financial targets following the PRA acquisition, positioning itself advantageously amid potential funding uncertainties in the market. Additionally, Icon's favorable client mix contributes to an improving win rate, enhancing its capacity to capitalize on the growing clinical trial research sector within the contract research organization market.
Bears say
Icon's stock outlook is negatively impacted by lowered EBITDA margin expectations, which have decreased to the high-19% range, compared to previous anticipations of around 20% for both the current year and 2025. Contributing factors to this outlook include uncertainties surrounding slowed clinical trial activity due to pharmaceutical companies reprioritizing their projects and broader biotech funding challenges. Additionally, potential risks such as inflationary pressures and a slowdown in Pharma R&D spending further complicate the company's revenue synergy projections from the PRA transaction.
This aggregate rating is based on analysts' research of ICON and is not a guaranteed prediction by Public.com or investment advice.
ICON (ICLR) Analyst Forecast & Price Prediction
Start investing in ICON (ICLR)
Order type
Buy in
Order amount
Est. shares
0 shares